Press Release // February 25, 2025
 

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea^®, under the brand name AHZANTIVE^®

• FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
• UK market authorization follows successful regulatory approvals by the FDA and the European Commission for FYB203
• Teva Pharmaceuticals will market FYB203 / AHZANTIVE^® in major parts of Europe, including the United Kingdom

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH (Klinge) jointly announce that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved FYB203 (aflibercept), a biosimilar to Eylea^®1, under the brand name AHZANTIVE^®2. The approval covers the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal conditions, including Diabetic Macular Edema (DME), visual impairment due to Myopic Choroidal Neovascularisation (CNV) and Macular Edema following Retinal Vein Occlusion (RVO).

“With the approval of FYB203, our second ophthalmic biosimilar in the UK, we take yet another significant step in making essential ophthalmic therapies more widely available,” said Dr. Stefan Glombitza, CEO of Formycon AG. “In addition to Ongavia^®3, our successful ranibizumab biosimilar in the UK, AHZANTIVE^® will provide a new, cost-efficient treatment option for patients with severe retinal diseases, through our strong commercial partner Teva.”

The U.S. Food and Drug Administration (FDA) had already granted marketing authorization for FYB203 in June 2024, followed by European Commission`s approval in January 2025.

Recently, Formycon and Teva Pharmaceuticals International GmbH (Teva) announced a partnership for the semi-exclusive commercialization of FYB203 across major parts of Europe, including the United Kingdom, and Israel. Concurrently, Formycon had concluded an agreement with Teva for product supply. Teva is already marketing Formycon’s FYB201 ranibizumab Biosimilar (Ongavia^®) in the UK and can synergistically leverage an existing commercial infrastructure and well-established distribution channels in the ophthalmology field.

Aflibercept is an inhibitor of the vascular endothelial growth factor (VEGF), which plays a key role in the abnormal formation of blood vessels in the retina, leading to vision impairment.

—————

¹⁾ Eylea^® is a registered trademark of Regeneron Pharmaceuticals Inc.
²⁾ AHZANTIVE^® is a registered trademark of Klinge Biopharma GmbH
³⁾ Ongavia^® is a registered trademark of Teva Pharmaceuticals Limited

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; FYB202 is also approved in Canada. Another four biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX and TecDAX selection indices. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

About Teva:
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing its generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110
Mail: Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

Berlin, 25 February 2025. Following a cyber-attack on the IT infrastructure of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) at the beginning of February, the Group’s business operations can continue in most areas. In a few cases, there are still restrictions due to the gradual restoration at one point or another. 

As of this week, all essential core systems are back in operation. In some cases, temporary solutions have been implemented to offer all business partners the full range of services again.

“We have temporarily converted some digital processes to manual processes in recent weeks. However, our production continues, and we can supply our customers,” explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. 

Eckert & Ziegler remains committed to upholding the highest standards of safety and integrity and thanks its patients, customers and partners for their patience and understanding during this incident.

“I would like to thank everyone involved for their tremendous efforts during the last few weeks. A special thanks goes to our colleagues in IT, who are giving their best to get us back up and running as quickly as possible. We kindly ask our business partners to continue to be understanding and patient if there are still temporary delays or restrictions in communication at the moment,” added Dr. Harald Hasselmann.

The Executive Board currently does not expect any significant adverse effects on the business.

Contact:
Eckert & Ziegler SE
Karolin Riehle
Investor Relations
Robert-Rössle-Str. 10
13125 Berlin
Tel. +49 30 94 10 84-138
Tel. +49 174 1785889
ir@ezag.com
www.ezag.com  

• Revenues of € 17.0 million
• EBIT of € 3.5 million, 21% margin
• Profit after tax € 4.6 million
• Forecast for fiscal year 2024/2025
  • Slight increase in sales from € 17.0 million to € 17.5 million
  • EBIT between € 3.5 million and € 4.0 million

Bremen, January 30, 2025 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, announces its results for the fiscal year 2023/2024, with reporting period October 1, 2023 to September 30, 2024.

Revenues in the past fiscal year 2023/2024 amounted to €17.0 million (compared to €17.3 million in fiscal year 2022/2023). 25 % of sales revenues (previous year: 26%) are attributable to the sale of licenses, 35 % (previous year: 36 %) to maintenance revenues and 40 % (previous year: 38 %) to other revenues, which include, among other things, services for and recharges to affiliated companies and the parent company. The decline in license revenues compared to the previous year is mainly due to lower demand from our customers Philips and Canon. Maintenance revenues have fallen due to lower maintenance revenues from our customer Hologic. The year-on-year improvement in other revenues is due to a slight increase in diagnostic services and the reallocation of staff costs, rent and additional costs.

EBIT (earnings before interest and taxes) fell from € 3,895 k in the previous year to € 3,500 k in 2023/2024, mainly due to lower revenues, lower other operating income and higher staff costs. The EBIT margin fell accordingly from 23 % to 21 %.

Due to the tax group, only a small amount of income taxes of €0.1 million were incurred in the past financial year, the same as in the previous year.

This results in earnings after taxes of € 4.6 million (27 % margin) for fiscal year 2023/2024, compared to € 4.9 million (28 % margin) in 2022/2023. The profit of € 4,561 k will be transferred to Varex Imaging Deutschland AG under the domination and profit and loss transfer agreement .

For fiscal year 2024/2025, stable to slightly growing revenues in the range of € 17.0 million to € 17.5 million are expected. In addition to stable revenues from customer Hologic, slightly increasing revenues in the lung and liver segments are expected. In the area of development services, we expect a stable course. For earnings before interest and taxes (EBIT) for fiscal year 2024/2025 we expect a result between € 3.5 million and € 4.0 million, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in sales and the simultaneous disproportionately low increase in staff costs are the main drivers for the positive outlook for EBIT.

The half-year financial report for fiscal year 2024/2025 will be published on May 27, 2025.

Contact:
Kirchhoff, Marcus / CEO

News Release

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

• CEO Christophe Weber to retire from Takeda in June 2026 after 12 years
• Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process

OSAKA, Japan and CAMBRIDGE, Massachusetts, January 30, 2025 – Takeda (TSE:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting held in June 2026. Mr. Weber will not hold a Board seat after retiring from Takeda.

“The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber’s remarkable leadership,” said Masami Iijima, chair of the Board of Directors meeting and of the Nomination Committee. “During Christophe’s 12 years of leadership, Takeda has transformed into a competitive, global R&D-driven biopharmaceutical company, with a long-term sustainable business model. We are grateful for his tremendous impact and for his continued leadership at Takeda and support to Julie over the next 18 months. Julie is an outstanding leader who has made significant contributions to the company, notably in leading the U.S. business and the Plasma-Derived Therapies Business Unit previously. She is an experienced, values-based leader who will fully uphold our corporate culture and expand the impact we can have for patients around the world.”

Commenting on the selection process, Mr. Iijima said that “after undergoing a multi-year succession process, the Board determined that Julie Kim is the best leader among a strong pool of both internal and external candidates. The selection process followed by the Nomination Committee and the Board has been thorough and exemplary.”

“For several years, I have worked with the Board to ensure a smooth succession,” said Christophe Weber. “Now is the right time to appoint my successor given our competitive growth outlook, new product launches expected from the second half of 2026 onwards and the anticipated retirement of some external independent directors in the coming years. The Board’s selection of Julie is outstanding. I have worked closely with Julie for the past six years and have witnessed firsthand her values, intellect, grit and dedication to our people and patients.”

“Takeda is a unique company, and I am deeply honored to have been chosen to lead it,” said Julie Kim. “Thanks to Christophe’s phenomenal leadership, Takeda has become a global biopharmaceutical powerhouse with a promising late-stage pipeline. I am excited to guide Takeda through the next phase, together with our exceptional and talented people, while staying true to our strong culture that is rooted in our values and shaped by a heritage of more than 240 years. I want to thank the Board of Directors for their confidence in me. I look forward to working with the Board, Takeda’s executive team and all colleagues to serve and create long-term value for patients, shareholders and society.”

About Christophe Weber

Christophe Weber joined Takeda in April 2014 as chief operating officer. He was named president and representative director in June 2014, and subsequently appointed CEO in April 2015. Under Mr. Weber’s leadership, Takeda has focused on enhancing competitiveness through globalization and R&D transformation, while fostering a diverse and inclusive work environment and reinforcing ethical values and corporate governance.

About Julie Kim

Julie Kim has been the president of the U.S. Business Unit and U.S. country head since 2022, and a member of the Takeda Executive Team since 2019. With three decades of experience in health care, Mrs. Kim has held leadership positions at global, regional, country and functional levels. Her extensive background covers a range of therapeutic areas, international market access, general management, marketing and emerging market development.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Contacts:

Takeda Media Relations

Amy Atwood (U.S. & Global)

amy.atwood@takeda.com

Aya Shishido (Japan)

aya.shishido@takeda.com

Takeda Investor Relations

Christopher O’Reilly

Christopher.oreilly@takeda.com

+81 (0) 90-6481-3412

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

###

(Attachment)

1. Changes in Appointment and Titles of Representative Directors

* Subject to election and appointment at the 150th Ordinary General Meeting of Shareholders and Board of Directors meeting in June 2026.

2. Biography of Newly Appointed Representative Director

*There are no ordinary shares held as of the filing date.

3. Effective Date of Changes (planned)

June 2026

Abivax Publishes 2025 Financial Calendar

PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar.

Monday, March 24, 2025 (after US Market closes)

2024 Annual Business and Financial Report (as of December 31, 2024)

• Press Release
• Universal Registration Document (Euronext)
• Annual Report on Form 20-F

Monday, June 2, 2025 (after US Market closes)

2025 Q1 Financial Results (as of March 31, 2025)

• Press Release
• Report on Form 6-K

Friday, June 6, 2025

 2025 Annual General Meeting (AGM)

• Live meeting in Paris, France

Monday, August 11, 2025 (after US Market closes)

2025 Half-Year Business and Financial Report (as of June 30, 2025)

• Press Release
• Half-Year Financial Report (Euronext)
• Report on Form 6-K

Monday, December 15, 2025 (after US Market closes)

2025 Q3 Financial Results (as of September 30, 2025)

• Press Release
• Report on Form 6-K

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business and financial objectives. Words such as “anticipate,” “expect,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the Company’s expectations for publishing its financial results throughout 2025. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 5, 2024 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

Aubagne, France | January 28, 2025

Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024
 

• Sales revenue at 2,780 million euros, in constant currencies¹ up +0.6 percent including non-organic contribution², (reported: + 0.2 percent, organic¹: – 0.7 percent in constant currencies)
• Underlying EBITDA¹ of 779 million euros, resulting margin at 28.0 percent; net profit of 175 million euros
• 2024 revenue and profitability targets fully met
• Order intake dynamics pick up significantly in second half of the year
• Overall, cautiously positive outlook for 2025: profitable growth expected

In a challenging environment, Sartorius Stedim Biotech, a leading provider of innovative technologies for the manufacture of biologics, closed the fiscal year with a solid performance. With sales revenue at prior-year level and high profitability, according to preliminary figures, the company fully achieved its financial targets³ as adjusted at mid-year. For 2025, management expects profitable, moderate growth above market level.

“In 2024, Sartorius Stedim Biotech has successfully navigated the challenges that the entire life science industry continued to face: both inventory destocking and muted investment activities at customers continued for longer than anticipated. Under these conditions, Sartorius Stedim Biotech performed better than the market segment, proving its strong competitive position. While we shouldn’t focus too much on individual quarters, it’s encouraging to see an increasingly positive trend with business picking up significantly during the second half of the year and especially in the last quarter.,” said René Fáber, CEO of Sartorius Stedim Biotech. “The industry is gradually returning to its robust, structural growth trend. For 2025, however, we remain cautious and assume that market growth is still likely to be below the long-term average for now. Against this backdrop, we expect moderate revenue growth above market level and increasing profitability for our company.”

Business development¹
In 2024, Sartorius Stedim Biotech generated sales revenue of 2,780 million euros, reaching the prior-year level. This corresponds to a slight growth of 0.6 percent in constant currencies¹ (reported: + 0.2 percent; organic: – 0.7 percent in constant currencies¹). Sales revenue includes a non-organic contribution² of 2.4 percent. Development in the consumables business was particularly positive, as most biopharma customers are reaching their target inventory levels and are gradually returning to an order level that corresponds to their production activities. Sales revenue from products for advanced therapies also continued to grow at an above-average rate, while business with bioprocessing equipment remained muted. Order intake¹ developed even better than revenue, increasing by a double-digit 12.9 percent in constant currencies (reported: + 12.3 percent).

As expected, business performance was particularly pronounced in the final quarter: between October and December, Sartorius Stedim Biotech achieved sales revenue of 751 million euros, an uptick of 6.1 percent in constant currencies¹ (reported: + 6.3 percent) compared with the previous year, while order intake¹ rose significantly by 23.8 percent in constant currencies.

Regional business performance varied in fiscal 2024. In the EMEA⁴ region, which accounts for around 42 percent of the Group’s business, sales revenue increased by 5.9 percent to 1,159 million euros. Despite the ongoing weakness of the Chinese market, the Asia | Pacific region grew by 4.0 percent to 639 million euros, thereby accounting for 23 percent of Group revenue. In the Americas region, on the other hand, sales revenue decreased by 6.7 percent to 982 million euros due to the continued subdued investment activity by customers. This corresponds to a share of 35 percent of the Group’s business.

The Group’s underlying EBITDA¹ came in slightly below the prior year, down 0.8 percent to 779 million euros, with the resulting margin remaining at a high level of 28.0 percent (PY: 28.3 percent).

Underlying net profit¹ totaled 338 million euros, compared with 386 million euros in the prior year, while net profit amounted to 175 million euros (PY: 310 million euros). Underlying earnings per share were 3.49 euros (PY: 4.19 euros) and earnings per share 1.81 euros (PY: 3.37 euros).

As of December 31, 2024, Sartorius Stedim Biotech employed 9,901 people worldwide, compared with 10,662 at the end of 2023.

With regard to its portfolio, Sartorius Stedim Biotech again expanded its product offering for biologics process development and manufacturing with a series of market launches. In addition to new products for customers working on cell and gene therapies, new products were launched in the areas of fluid management and filtration. Furthermore, partnering with a major customer, the Group developed a platform for continuous manufacturing which will allow for significantly higher efficiency and thus reduced resource consumption.

Key financial indicators
Sartorius Stedim Biotech’s key financial indicators remain at highly robust levels. Equity was 4,024 million euros as of December 31, 2024; the equity ratio¹ increased significantly to 48.7 percent (December 31, 2023: 2,674 million euros and 34.6 percent, respectively), mainly as a result of the capital increase successfully completed at the beginning of February 2024.

Net operating cash flow was up by 9.2 percent to 815 million euros, compared with 746 million euros in the prior-year period, particularly due to the planned reduction of working capital¹. Investments in research and the company’s global production infrastructure amounted to 340 million euros (PY: 474 million euros). The ratio of capital expenditures (capex) to sales revenue stood at 12.2 percent at year-end as projected (PY: 17.1 percent). Gross debt decreased to 2,869 million euros (December 31, 2023: 3,682 million euros), net debt to 2,191 million euros, and the ratio of net debt to underlying EBITDA¹ to 2.8, as forecast (December 31, 2023: 3,565 million euros and 4.5, respectively).

Deliberately cautious outlook for fiscal 2025: profitable growth targeted
For fiscal 2025, Sartorius Stedim Biotech expects continuous demand recovery and growth in the life science market, albeit at a rate still below its long-term average. In this environment, the company intends to grow profitably above market level, and to achieve a moderate increase in sales revenue, which is likely to be driven primarily by recurring business with consumables. Based on the expected volume development, positive product mix effects and supported by the effects of the previous year’s efficiency program, the company forecasts that underlying EBITDA should increase over-proportionately compared with sales revenue. In 2025, Sartorius Stedim Biotech will continue its organic debt reduction course with a focus on working capital and managing investments.

The company will provide a quantitative forecast after the first quarter of 2025.

1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving comparability of business performance over time and within the industry.
 

• Constant currencies: figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
• Organic: organic growth figures exclude the impact from changes in exchange rates and changes in the scope of consolidation
• Order intake: all customer orders contractually concluded and booked during the respective reporting period
• Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
• Underlying net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, and based on the normalized financial result and the normalized tax rate
• Equity ratio: equity in relation to the balance sheet total
• Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period
• Working capital: sum of inventories and trade receivables

2 Acquisition of Polyplus
3 Forecast for fiscal year 2024 as of July 2024
4 EMEA = Europe, Middle East, Africa

This media release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.
Management points out that dynamics and volatilities in the industry have increased significantly in recent years. In addition, uncertainties due to the changed geopolitical situation, such as the emerging decoupling tendencies of various countries, are playing a greater role. This results in higher uncertainty when forecasting business figures.

Conference call
René Fáber, CEO of the Sartorius Stedim Biotech Group, will discuss the company’s business results with analysts and investors in a conference call at 1.00 p.m. CET on January 28, 2025.
Register here: Conference Call on the Preliminary Results 2024



Financial calendar
February 17, 2025          Publication of Annual Report
March 25, 2025                Annual Shareholders’ Meeting
April 16, 2025                   Publication of the first quarter results January to March 2025
July 22, 2025                    Publication of the half-year results January to June 2025
October 16, 2025            Publication of the nine-month results January to September 2025

Preliminary key figures for the full year of 2024
 

1 cc = constant currency: Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
2 All customer orders contractually concluded and booked during the respective reporting period
3 According to customer location
4 Earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items
5 Profit for the period after non-controlling interest, adjusted for extraordinary items, and amortization, as well as based on the normalized financial result and the normalized tax rate 
6 After non-controlling interest
7 The previous year’s figures have been revised due to finalization of the purchase price allocation for the acquisition of Polyplus                      



Reconciliation of alternative performance measures

Reconciliation between EBIT and underlying EBITDA

The previous year’s figures have been revised due to finalization of the purchase price allocation for Polyplus.
Reconciliation between EBIT and underlying net result

1 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities and change in valuation of earn-out liability
2 Normalized income tax based on the underlying profit before taxes and non-cash amortization

The previous year’s figures have been revised due to finalization of the purchase price allocation for the acquisition of Polyplus                      

Calculation of net debt and ratio of net debt to underlying EBITDA

Calculation of the capital expenditures ratio

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros, according to preliminary figures. Currently, more than 9,900 employees are working for customers around the globe.

Visit our newsroom and follow us on LinkedIn.

Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
 

Financial Year 2024 (preliminary):

• Sales of around EUR 295 million (previous year:  EUR 246.1 million)
• EBIT before special items of around EUR 66 million (previous year: EUR 46.9 million)
• Net Income of around EUR 33 million (previous year: EUR 26.3 million)

Berlin, 27 January 2025. According to preliminary, unaudited figures, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of around EUR 295 million and an adjusted EBIT of around EUR 66 million in the 2024 financial year. Sales increased by 20% compared to the previous year. Adjusted EBIT is even 41% higher than in the previous year and thus above the raised forecast for FY 2024 issued on 22 November 2024. Net profit (from continued and discontinued operations), which is only reported here for comparison purposes, rose to around EUR 33 million (previous year: EUR 26.3 million).

The guidance for the 2025 financial year will be published on 27 March 2025 together with the complete, audited annual financial statements for 2024.

Contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com